Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
SupremeCure Pharma Inc
Velacor Therapeutics Pty Ltd
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PP2A for Castration Resistant Prostate Cancer and Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: First two patients enrolled in tiol Cancer Institute trial of the ability of Lixte Biotechnology’s LB-100 to enter recurrent malignt Brain Tumors
Aug 06, 2019: The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
Jul 18, 2019: First patient enrolled in phase 1b/2 trial of Lixte Biotechnology’s LB-100 in low or intermediate-1 Risk Myelodysplastic Syndrome
Jun 25, 2019: Lixte Biotechnology’s PP2A inhibitor, LB-100, improves brain function and motor impairment in a mouse model of Angelman syndrome, a rare human neurodevelopmental disorder
May 16, 2019: PEP-Therapy reports positive results from GLP-Toxicity study of PEP-010 drug candidate
May 15, 2019: Lixte Biotechnology’s LB-100 to be evaluated by the tiol Cancer Institute in a clinical study of LB-100’s ability to enter recurrent Glioblastoma Multiforme brain tumors
Nov 05, 2018: FDA approves Lixte Biotechnology’s IND to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center
Oct 09, 2018: Lixte Biotechnology files an IND with the FDA to conduct a phase 1b/2 trial of LB-100 in patients with myelodysplastic syndrome at Moffitt Cancer Center
Apr 17, 2018: PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 M? to Develop a Novel Peptide in Oncology
Feb 09, 2018: LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kise Inhibitors
Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO Intertiol for partnering
Apr 17, 2017: Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combition with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Nov 03, 2016: Re-Pharm to present at IDDST, njing, Chi and available for one-to-one meetings
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
Pipeline by PEP-Therapy SAS, H2 2019
Pipeline by Re-Pharm Ltd, H2 2019
Pipeline by SupremeCure Pharma Inc, H2 2019
Pipeline by Velacor Therapeutics Pty Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019